PCCTC investigator and PCWG4 co-primary author Dr Andrew Armstrong: PCWG4 Amends Terminology and Biomarker Standards for Advanced Prostate Cancer www.urotoday.com/video-lectur...

PCCTC Investigator and 2025 PCF Lifetime Achievement Award for Women in Science recipient Dr Maha Hussain on lessons from a career in prostate cancer clinical trial leadership: www.urotoday.com/video-lectur...

PCCTC investigator @dangeorgemd.bsky.social on individualized goals and shared decision-making in mHSPC care via UroToday: www.urotoday.com/video-lectur...

First quadruplet therapy regimen shows promise for men with metastatic high-volume metastatic androgen pathway modulation–naïve prostate cancer. CASCARA clinical trial results published in Clinical Cancer Research: www.pcctc.org/news/first-q...

Emerging Concepts in Detecting and Treating Prostate Cancer: An Interview with Daniel George, MD | Diagnostic Imaging Can the radioligand therapy 177Lu-PSMA-617 have an impact in older taxane-naïve men with mCRPC? Could we see the development of more combination therapies for patients with prostate cancer? Will emerg...

PCCTC investigator @dangeorgemd.bsky.social on emerging concepts in detecting and treating prostate cancer via Diagnostic Imaging: www.diagnosticimaging.com/view/emergin...

Sean McBride: Our AASUR Trial in High-Risk Prostate Cancer - OncoDaily Sean McBride: Our AASUR Trial in High-Risk Prostate Cancer / cancer, Channing J Paller, Curtiland Deville, Dana Rathkopf, Daniel E Spratt, Han Xiao, Howard

Dr @seanmmcbride.bsky.social on the PCCTC-managed AASUR Trial in High-Risk Prostate Cancer via @oncodaily.bsky.social: oncodaily.com/voices/sean-...

Advancing the Standard: How the PCCTC Led the Science at the 2026 ASCO GU Symposium and Forged New Paths for Collaboration The 2026 American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was a landmark event for the Prostate Cancer Clinical Trials Consortium (PCCTC), and I could not be prouder of...

Advancing the Standard: How the PCCTC Led the Science at the 2026 ASCO GU Symposium and Forged New Paths for Collaboration www.linkedin.com/pulse/advanc...

#gu26 #prostatecancer | OncoAlert Just Published at JCO & POSTER NOW BEING PRESENTED 11:30-12:45pm ABSTRACT 162 Poster Bd E17 ( ⭐ Please Visit ⭐ ) American Society of Clinical Oncology (ASCO) #GU26 Trial Design and Objectives for P...

PCCTC SOC Chair and PCWG4 Co-Lead Author @mjmorrismd.bsky.social discusses Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 with @oncoalert.bsky.social www.linkedin.com/feed/update/...

‼️#GU26 simultaneous publication by @AarmstrongDuke et al: 

Trial Design and Objectives for Patients with Prostate Cancer: Recommendations From Prostate Cancer Working Group 4

Learn more: https://bit.ly/46dupmq

#gu26 #prostatecancer | OncoAlert Just Published at JCO and out for #GU26 Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 https://lnkd.in/dqfJFynp Here is Dr An...

PCCTC investigator and PCWG4 co-lead author Dr Andrew J. Armstrong discusses the new prostate cancer trial design recommendations with OncoAlert: www.linkedin.com/feed/update/...

Just published! Prostate Cancer Working Group 4 recommendations are now available in the Journal of Clinical Oncology, providing updated standards for clinical trial design, patient eligibility, and outcome measures in advanced prostate cancer: ascopubs.org/doi/pdfdirec...

We’re excited to highlight the groundbreaking research being shared tomorrow by PCCTC investigators at #GU26! From cutting-edge clinical trial results to revised PCWG4 guidelines, these abstracts showcase the passion and progress driving the future of prostate cancer care.

K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with...

K36 Therapeutics Highlights PCCTC-managed First-in-Human KTX-2001 Prostate Cancer Study Design at #GU26 www.prnewswire.com/news-release...

Prostate Cancer Working Group 4: What Does Its Work Mean for the Busy Clinician? At the 2026 ASCO Genitourinary Cancers Symposium, the international, multidisciplinary Prostate Cancer Working Group 4 will present its multiyear work to address unmet needs in the field of clinical r...

Prostate Cancer Working Group 4: What Does Its Work Mean for the Busy Clinician? #ASCODailyNews speaks with PCCTC investigators Drs Michael Morris and Andrew Armstrong: dailynews.ascopubs.org/do/prostate-...

PCCTC Investigator Dr. Maha Hussain to Present BRCAAway Prostate Cancer Trial Results at #GU26 Showing Median Survival Exceeding 5 Years with Abiraterone Plus Olaparib www.pcctc.org/news/landmar...

Prostate Cancer Working Group 4 Unveils Updated Global Standards for Advanced Prostate Cancer Clinical Trials at 2026 ASCO GU Symposium — The PCCTC The Prostate Cancer Clinical Trials Consortium today presented the Prostate Cancer Working Group 4 (PCWG4) clinical trials guidelines at the 2026 American Society for Clinical Oncology Genitourinary ...

We are pleased to announce the first public presentation of updated global standards for advanced prostate cancer clinical trials, Prostate Cancer Working Group 4 (PCWG4), at #GU26: www.pcctc.org/news/prostat...

PCCTC Investigators To Showcase Groundbreaking Prostate Cancer Research at 2026 ASCO GU Symposium (#GU26): www.pcctc.org/news/pcctc-i...

The Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group Criteria (#PCWG4) with guests PCCTC SOC chair @mjmorrismd.bsky.social and PCCTC investigator Dr Andrew Armstrong: creators.spotify.com/pod/profile/...

K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel targeted therapies for cancers with high...

K36 Therapeutics Completes Dosing of First Cohort in PCCTC-Managed Phase 1 Clinical Trial of NSD2 Inhibitor KTX-2001 in Prostate Cancer www.prnewswire.com/news-release...

PCCTC investigators Drs. Mary-Ellen Taplin and Andrew Armstrong discuss ASCO's first living guidelines for prostate cancer: www.oncologynewscentral.com/prostate-can...

In an effort by PCCTC investigators and colleagues, the importance of racial diversity in future genomic profiling and clinical trials efforts is highlighted. Full manuscript: pmc.ncbi.nlm.nih.gov/articles/PMC...

Dr George on the Role of Radioligand Therapy in Prostate Cancer Management | OncLive Daniel J. George, MD, discusses the potential of radioligand therapies for patients with prostate cancer and the evolution of this treatment paradigm.

PCCTC investigator @dangeorgemd.bsky.social of Duke University discusses the role of radioligand therapy in prostate cancer management: www.onclive.com/view/dr-geor...

The PCCTC plans on hiring three summer interns to support our Data Management, Data Science, and Clinical Operations teams. The 10-week internships are full-time, paid, 100% remote, and working hours are 9-5 EST. To learn more visit www.pcctc.org/news/2026-su...

Prostate Cancer Clinical Trials Consortium (PCCTC) Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum Leading clinical oncology stakeholders gathered in San Diego on 4 November for a half-day symposium hosted by Biocom California in partnership with the UC San Diego Moores Cancer Center, titled Innova...

Prostate Cancer Clinical Trials Consortium (PCCTC) Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum www.linkedin.com/pulse/prosta...

Just published - DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis www.nature.com/articles/s41...

The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...

#usaclinicaltrials #brany #wcgirb #nct07103018 | K36 Therapeutics, Inc. We’re thrilled to announce that our first site is officially activated for the KTX-2001 prostate cancer trial at #USAClinicalTrials in San Antonio, Texas! From regulatory packet submission to site ini...

The first site for the first-in-human KTX-2001 STRIKE-001 prostate cancer study has been activated at USA Clinical Trials (San Antonio, TX)—setting a PCCTC benchmark from reg packet distribution to site initiation. www.linkedin.com/posts/k36-th...

#lacog | LACOG - Latin American Cooperative Oncology Group Today we had the pleasure of welcoming representatives from the Prostate Cancer Clinical Trials Consortium (PCCTC) to the LACOG Office, together with Dr. André Poisl Fay, Brazil Investigator Lead for ...

We are proud to collaborate with the Latin American Cooperative Oncology Group (LACOG) on innovative multicenter clinical studies like DORA and the IRONMAN Registry www.linkedin.com/embed/feed/u...

PCCTC investigators publish results from the phase 1b DeLLpro-300 study of tarlatamab in patients with neuroendocrine prostate cancer: aacrjournals.org/clincancerre...

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPI: A Multinational Real-World Analysis of the IRONMAN Registry. Story via UroToday: www.urotoday.com/conference-h...